DoW Multiple Sclerosis Clinical Trial Award

US Dept › of the Army -- U › S › Army Medical Research Acquisition Activity (USAMRAA) grant open #HT942526MSRPCTA

Response due Aug 13, 2026 · 00:00 UTC

Summary

The Department of the Army (USAMRAA) is soliciting proposals for a Multiple Sclerosis Clinical Trial Award under the Department of Defense's congressionally directed medical research programs. This opportunity supports clinical trial research focused on multiple sclerosis. The solicitation is posted on Grants.gov as a synopsis, indicating a forthcoming or active funding opportunity announcement. Full scope details are not provided in the synopsis text.

What they want

The opportunity is posted as a synopsis for a Multiple Sclerosis Clinical Trial Award issued by the U.S. Army Medical Research Acquisition Activity (USAMRAA) under DoD agency code DOD-AMRAA. The award is intended to fund clinical trial research related to multiple sclerosis. The synopsis was opened on 05/05/2026 with a close date of 08/13/2026. No detailed scope of work, deliverables, technical requirements, or evaluation criteria are included in the synopsis text.

How they evaluate

Submission: Grants.gov federal grants portal

Risks & flags

Extremely limited scope information provided in synopsis — full requirements, eligibility, and evaluation criteria are not disclosed
Short synopsis with no budget, deliverables, or technical requirements listed — limited competitive intelligence available
Solicitation number format (HT9425) is consistent with USAMRAA CDMRP awards, which sometimes have narrowly defined eligibility requirements not visible at synopsis stage

Market context

inferred from NAICS

Professional, Scientific & Technical Services

NAICS 541714

US market size: $2.0T
Typical award: $25K – $50M

Typical buyers

All federal civilianDoDStates

Commonly required

8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.

DoW Multiple Sclerosis Clinical Trial Awar…

Due Aug 13

Onboard ↗